iECURE Revenue and Competitors
Estimated Revenue & Valuation
- iECURE's estimated annual revenue is currently $2.7M per year.
- iECURE's estimated revenue per employee is $77,500
- iECURE's total funding is $115M.
Employee Data
- iECURE has 35 Employees.
- iECURE grew their employee count by 30% last year.
iECURE's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Therapeutic Area Lead, Urea Cycle Disorders | Reveal Email/Phone |
3 | VP, Finance and Accounting | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | VP Head Technical Operations | Reveal Email/Phone |
6 | VP Regulatory Affairs | Reveal Email/Phone |
7 | VP Project Management & Patient Advocacy | Reveal Email/Phone |
8 | VP, Therapeutic Area Lead | Reveal Email/Phone |
9 | VP, Project Management & Patient Advocacy | Reveal Email/Phone |
10 | VP, Head Technical Operations | Reveal Email/Phone |
iECURE Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is iECURE?
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functioning genes into patients’ genomes, which offers long-term, stable expression of those genes. With our team’s proven track record, as well as the University of Pennsylvania’s deep expertise and translational genetic medicine engine, reversing the course of these devastating diseases is now within reach.
keywords:N/A
$115M
Total Funding
35
Number of Employees
$2.7M
Revenue (est)
30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
iECURE News
Dr. Diaz joins iECURE with more than 25 years of experience in urea cycle disorders and other metabolic diseases and monogenic disorders.
Other Companies in Philadelphia
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.1M | 35 | N/A | N/A |
#2 | $6.2M | 35 | 52% | N/A |
#3 | $4.1M | 35 | 9% | N/A |
#4 | $7.6M | 35 | 0% | N/A |
#5 | $15M | 35 | 3% | N/A |